Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 3.85B 3.35B 3.13B 2.87B 5.41B 367B 5.51B 36.88B 14.45B 183B 14.48B 14.16B 604B P/E 2024
15.9x
P/E 2025 13.9x
Enterprise Value 3.15B 2.74B 2.55B 2.35B 4.42B 300B 4.5B 30.12B 11.8B 150B 11.83B 11.56B 494B EV / Sales 2024
4.02x
EV / Sales 2025 3.67x
Free-Float
99.94%
Yield 2024 *
-
Yield 2025 -
1 day+0.03%
1 month+0.13%
3 months+9.57%
6 months+24.86%
Current year+34.92%
1 month 31.45
Extreme 31.45
31.5
Current year 22.13
Extreme 22.13
32.56
1 year 19.05
Extreme 19.05
32.56
3 years 11.55
Extreme 11.55
32.56
5 years 4.81
Extreme 4.81
32.56
10 years 0.73
Extreme 0.73
32.56
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2024
Director of Finance/CFO 55 01/01/2024
Chief Tech/Sci/R&D Officer 62 01/06/2025
Director TitleAgeSince
Director/Board Member 48 15/07/2026
Director/Board Member - 15/07/2026
Director/Board Member - 15/07/2026
Date Insider Type Main position Quantity % Market Cap.
15/7/26 Issuer sale

Director

-63,583 0.0519%
15/7/26 Issuer sale

Director

-130,857 0.1069%
15/7/26 Issuer sale

Executive/Senior Manager

-1,051,183 0.8587%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-.--%+49.10%+132.40% 3.85B
-0.44%+13.80%+35.85%-1.58% 75.81B
+1.31%-10.35%+21.47%+181.93% 48.57B
-4.18%+42.30%+42.30%+42.30% 46.01B
+3.64%+7.79%-51.37%-51.41% 41.66B
-0.56%+0.84%+52.95%-24.62% 29.82B
-0.91%-0.37%+56.67%+82.26% 24.01B
+0.58%-0.88%+99.75%-49.85% 22.01B
+0.81%-3.56%-6.67%+164.33% 19.09B
+0.23%-6.26%+62.19%+116.42% 15.83B
Average +0.29%-0.77%+36.23%+59.22% 32.67B
Weighted average by Cap. +0.05%+0.93%+29.84%+43.33%

Financials

2024 2025
Net sales 492M 427M 399M 366M 691M 46.87B 703M 4.7B 1.84B 23.37B 1.85B 1.81B 77.09B 589M 512M 478M 439M 827M 56.14B 842M 5.64B 2.21B 28B 2.21B 2.16B 92.34B
Net income 164M 142M 133M 122M 230M 15.62B 234M 1.57B 614M 7.79B 616M 602M 25.69B 214M 186M 174M 160M 301M 20.43B 306M 2.05B 803M 10.19B 805M 787M 33.6B
Net Debt -514M -447M -417M -383M -722M -49.03B -735M -4.92B -1.93B -24.45B -1.93B -1.89B -80.64B -706M -614M -573M -526M -992M -67.33B -1.01B -6.76B -2.65B -33.58B -2.65B -2.59B -111B
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. CPRX Stock